2 Results
NIAID Announces Antiviral Drug Development Awards
May 18, 2022
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
NIAID Pandemic Preparedness Plan Targets ‘Prototype’ and Priority Pathogens
February 2, 2022
As the global COVID-19 pandemic continues into its third year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is focusing on preparing for a range of other viral threats that could cause a public health emergency. For decades, NIAID has launched major research responses and developed medical countermeasures to combat multiple emerging infectious diseases, including HIV/AIDS, SARS-CoV-1, Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, Zika virus, and SARS-CoV-2.
